Data protection Impressum

Pharma

ten23 health celebrates the opening of its VIVA2® facility in Visp, increasing the region's sterile pharmaceutical production capacity and strengthening its position in the life sciences sector.

ten23 health inaugurates VIVA2 sterile production facility in Visp

24 September 2024

HAYA Therapeutics has announced a multi-year collaboration with Eli Lilly, potentially earning up to USD 1 billion in milestone payments to advance RNA-guided therapies for obesity and metabolic disorders.

HAYA Therapteutics enters major collaboration to advance RNA-based drug discovery

17 September 2024

Relief Therapeutics has entered into an agreement with SWK Funding LLC to secure up to USD 11 million in non-dilutive financing through the sale of royalty interests to support its clinical development pipeline.

Geneva biotech Relief Therapeutics raises up to USD 11 million from royalty sales

14 August 2024

Release Therapeutics has raised CHF 3.3 million in seed funding to advance its innovative approach to treating metachromatic leukodystrophy (MLD), a rare genetic disorder affecting young children.

Release Therapeutics secures CHF 3.3 million to advance MLD research

13 August 2024

Oryl Photonics has joined the Fast and Accurate Solubility for Sustainability (FASS) project, receiving a EUR 2.5 million EIC Transition grant to develop a novel laboratory instrument for drug solubility measurement.

EPFL spin-off Oryl Photonics joins a EUR 2.5 million European project

7 August 2024

AC Immune’s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

AC Immune receives FDA Fast Track designation for Alzheimer’s disease therapy

6 August 2024

Biopôle is joining forces with Swiss Healthcare Startups to extend the Vanguard accelerator to digital health start-ups in German-speaking Switzerland, while also welcoming Hôpital de La Tour to its Corporate Partnership Programme.

Biopôle expands its accelerator program and welcomes new corporate partner

5 August 2024

Top Stories Western Switzerland

Top Stories from Western Switzerland (July 2024)

17 July 2024

Asceneuron has secured USD 100 million in Series C funding to advance its mission of developing OGA inhibitors for neurodegenerative diseases like Alzheimer's.

Asceneuron raises USD 100 million to advance Alzheimer’s treatment

16 July 2024

Global demand for biologics is at an all-time high, and Western Switzerland is positioning itself as a key player in meeting that demand.

Biomanufacturing in Western Switzerland

1 2 3 4 5 6 7 8 9 10 11